We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Transdermal Fentanyl in Patients with Cachexia—A Scoping Review.
- Authors
Carlini, Andrea; Scarpi, Emanuela; Bettini, Carla; Ardizzoni, Andrea; Donati, Costanza Maria; Fabbri, Laura; Ghetti, Francesca; Martini, Francesca; Ricci, Marianna; Sansoni, Elisabetta; Tenti, Maria Valentina; Morganti, Alessio Giuseppe; Bruera, Eduardo; Maltoni, Marco Cesare; Rossi, Romina
- Abstract
Simple Summary: This scoping review explores the use of transdermal fentanyl (TDF) for pain management in patients with cachexia, which is a severe wasting syndrome associated with cancer and other advanced illnesses. While TDF is commonly used in the management of chronic cancer-related and non-cancer related pain, its efficacy and safety in cachectic patients remain unclear due to altered pharmacokinetics (PK) in these individuals. This review examines nine studies that analyzed the impact of cachexia on the efficacy and tolerability of TDF. The findings suggest mixed results: some studies showed that cachexia could reduce TDF effectiveness and increase the required dose, while others found little to no impact or even potential improvement in outcomes. The current evidence is insufficient to provide definitive guidelines for the use of TDF in cachectic patients, highlighting the need for further research in this area. Cachectic patients frequently require transdermal fentanyl (TDF) for pain management, but data on its efficacy and safety are scarce and inconsistent. This scoping review aims to analyze the evidence concerning TDF administration in patients with cachexia irrespective of the underlying pathology. The primary objective is to assess the analgesic efficacy and tolerability of TDF in cachectic patients. The secondary objective is to identify cachexia characteristics that may influence fentanyl pharmacokinetics (PK). A comprehensive search of PubMed, Embase, and Web of Science databases was conducted up to March 2024. The review included observational and clinical studies on cachectic patients with moderate to severe pain treated with TDF patches at any dosage or frequency. Phase 1 trials, animal studies, case reports, preclinical studies and conference abstracts were excluded. Nine studies were included: four studies reported that cachexia negatively impacted TDF efficacy, increasing required doses and lowering plasma concentrations; three studies found minimal or no impact of cachexia on TDF efficacy and PK; two studies suggested that cachexia might improve TDF outcomes. Study quality ranged from moderate to high, according to the National Institutes of Health (NIH) Quality Assessment Tool. The current evidence is insufficient to provide any definitive recommendations for TDF prescribing in cachectic patients.
- Subjects
MEDICAL information storage &; retrieval systems; BODY mass index; DESCRIPTIVE statistics; SYSTEMATIC reviews; MEDLINE; DRUG efficacy; LITERATURE reviews; PAIN management; CACHEXIA; TRANSDERMAL medication; ONLINE information services; ALBUMINS; QUALITY assurance; FENTANYL; DRUG tolerance
- Publication
Cancers, 2024, Vol 16, Issue 17, p3094
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers16173094